China NMPA Conditionally Approves Iparomlimab and Tuvonralimab Injection for Marketing

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#NMPA #Iparomlimab #Tuvonralimab #Qibeian #CervicalCancer #Immunotherapy #BispecificAntibody #QiluPharmaceutical #ChineseInnovativeDrugs #Oncology

Iparomlimab and Tuvonralimab: First Approval - Drugs Iparomlimab and tuvonralimab (齐倍安®) is a bifunctional combination of anti-programmed death receptor-1 (PD-1)/anti-cytotoxic T lymphocyte-associated protein-4 (CTLA-4) monoclonal antibodies (mAbs) bein...

#immunosky This study summarizes the milestones in the development of #iparomlimab & #tuvonralimab leading to this first approval for the treatment of patients with recurrent or metastatic cervical cancer who have failed previous platinum-based chemotherapy. link.springer.com/article/10.1...